Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;7(10):e2441380.
doi: 10.1001/jamanetworkopen.2024.41380.

Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management

Kevin Lin  1 , Ateev Mehrotra  2 , Thomas C Tsai  3
Affiliations

Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management

Kevin Lin et al. JAMA Netw Open. .

Erratum in

  • Coding and Duplication Errors.
    [No authors listed] [No authors listed] JAMA Netw Open. 2025 Feb 3;8(2):e251603. doi: 10.1001/jamanetworkopen.2025.1603. JAMA Netw Open. 2025. PMID: 39969888 Free PMC article. No abstract available.
No abstract available

Plain language summary

This cross-sectional study investigates rates of bariatric surgery and glucagon-like peptide-1 receptor agonist prescription among adults with obesity in 2022 to 2023.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tsai reported receiving grants from the National Center for Advancing Translational Sciences, National Institutes of Health to Harvard Catalyst, the Harvard Clinical and Translational Science Center, and financial contributions from Harvard University and its affiliated academic health care centers. No other disclosures were reported.

Figures

Figure.
Figure.. Quarterly Trends in Obesity Treatment, 2022-2023
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and metabolic bariatric surgery use are tracked across 2022 to 2023 quarters. The number of patients who received a metabolic bariatric surgery per 1000 individuals (A) and the number of patients prescribed a GLP-1 RA per 1000 individuals (B) are shown.
See this image and copyright information in PMC

References

    1. Brown C. High price and demand for semaglutide means lack of access for US patients. BMJ. 2023;382:1863. doi:10.1136/bmj.p1863 - DOI - PubMed
    1. Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003). 2024;64(1):133-138. doi:10.1016/j.japh.2023.10.002 - DOI - PubMed
    1. Quan H, Sundararajan V, Halfon P, et al. . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. doi:10.1097/01.mlr.0000182534.19832.83 - DOI - PubMed
    1. Chhabra KR, Fan Z, Chao GF, Dimick JB, Telem DA. The role of commercial health insurance characteristics in bariatric surgery utilization. Ann Surg. 2021;273(6):1150-1156. doi:10.1097/SLA.0000000000003569 - DOI - PubMed
    1. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795-1797. doi:10.1001/jama.2023.19574 - DOI - PMC - PubMed

LinkOut - more resources